Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes

Figure 3

Glucose homeostasis in C57BL/6J mice consuming an MCDD is improved by the administration of dapagliflozin. (a) ipGTT in mice after 17 weeks of consumption of an NCD, HFD, or HFD + MCDD (top panel; per group). The areas under the glucose curve (AUC glucose) for each group during the ipGTT are shown in the second panel. In addition, the glucose curve during an ipITT are shown in the third panel ( per group). The plasma insulin concentrations of mice from each group fasted overnight for 16 hours (bottom panel; per group). compared with the NCD- or HFD + MCDD-fed groups. ^† and ^¶ compared with the NCD-fed group. (b) ipGTT glucose profiles (top panel) and AUC glucose (middle panel) for mice fed an NCD and treated with PBS, or 0.1 or 1.0 mg/kg/day dapagliflozin (Dapa 0.1 or 1.0) for 2 weeks ( per group). The ipITT glucose profiles are shown in the bottom panel ( per group). (c) ipGTT glucose profiles (top panel) and AUC glucose (middle panel) in mice consuming an HFD that were treated with PBS, or 0.1 or 1.0 mg/kg/day dapagliflozin (Dapa 0.1 or 1.0) for 2 weeks ( per group). The ipITT glucose profiles are shown in the bottom panel ( per group). vs. the Dapa 0.1 or 1.0-treated groups. (d) ipGTT glucose profiles (top panel) and AUC glucose (middle panel) in mice consuming an HFD + MCDD that were treated with PBS, or 0.1 or 1.0 mg/kg/day dapagliflozin (Dapa 0.1 or 1.0) for 2 weeks ( per group). The ipITT glucose profiles are shown in the bottom panel ( per group). compared with the Dapa 1.0-treated group.

(a)

(b)

(c)

(d)